Search

Displaying results 1711 - 1720 of 5419 in total
  1. Drug

    Moroctocog alfa

    go.drugbank.com/drugs/DB13999
    Approved

    Use of recombinant DNA-derived clotting factor treatments, such as Moroctocog alfa, has reduced this risk. … Moroctocog alfa is identical in sequence to endogenously produced Factor VIII, but does not contain the B-domain, which has no known biological function.

  2. Drug

    Gadoxetic acid

    go.drugbank.com/drugs/DB08884
    ApprovedInvestigational

    [A263146] Gadoxetic acid, under the form gadoxetate disodium, is marketed by Bayer HealthCare Pharmaceuticals under the brand name EOVIST and FDA approved in 2008.[A263151] … [A263146] Since gadoxetate uptake is mediated by organic anion-transporting polypeptides (OATPs) and liver tumor cells lack OATPs, liver tumors show a lack of contrast of enhancement and therefore heightening

  3. Drug

    Pretomanid

    go.drugbank.com/drugs/DB05154
    ApprovedInvestigational

    It was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019.

    Categories: Antiinfectives for Systemic Use
  4. Drug

    Afamitresgene autoleucel

    go.drugbank.com/drugs/DB18592
    ApprovedInvestigational

    [L51114] MAGE-A4 is an intracellular cancer-testis antigen that is overexpressed by cancer cells in synovial sarcoma.

    Synonyms: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE
  5. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … It is available under the brand name Olita made by Hanmi Pharmaceuticals [A19196]. Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim.

  6. Drug

    Factor XIII (human)

    go.drugbank.com/drugs/DB12909
    ApprovedInvestigational

    When activated by thrombin at the site of injury, the FXIII pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit. … Factor XIII (Human), available as the commercially available product Corifact, is approved by the Food and Drug Administration for routine prophylactic treatment and peri-operative management of surgical

  7. Drug

    Guaifenesin

    go.drugbank.com/drugs/DB00874
    ApprovedInvestigationalVet approved

    Guaifenesin possesses a storied history, having been originally formally approved by the US FDA in 1952 and continues to be one of very few - if not perhaps the only drug that is readily available and … After the negotiation between FDA and major manufacturers, a voluntary transition of labels for not using guaifenesin in children under the age of 4 years was endorsed by FDA in 2008 [F4525].

    Products: Siltussin SA, Compresso Ggf 95 Sa
  8. Drug

    Fibrinogen human

    go.drugbank.com/drugs/DB09222
    ApprovedInvestigational

    It works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting.

  9. Drug

    Aluminum zirconium trichlorohydrex gly

    go.drugbank.com/drugs/DB11116
    ApprovedWithdrawn

    Aluminum zirconium trichlorohydrex gly is a common active ingredient in deodorant and antiperspirant products for the over-the-counter use.

  10. Drug

    Ticagrelor

    go.drugbank.com/drugs/DB08816
    ApprovedInvestigational

    [A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010.